Rhythm Pharmaceuticals, Inc.RYTM
NasdaqGM•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $217.16M, growing 58.7% year-over-year. TTM net income stood at $-202.68M (20.1% contraction). Quarterly EBITDA was $-52.36M and operating income was $-52.36M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze RYTM growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters